SPONSOR
ArriVent BioPharma, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 3, Phase 1
Conditions studied: Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung CancerEGFR P-Loop and Alpha C-Helix CompressingEGFR PACCEGFR Uncommon MutationsLocally Advanced or Metastatic Solid TumorsColorectal CancerGastric CancerPancreatic Cancer
Clinical Trials by ArriVent BioPharma, Inc.
NCT07185997 Phase 3
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-Small-Cell Lung Cancer
NCT07066657 Phase 1
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Locally Advanced or Metastatic Solid Tumors
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology